ENERGIZE logo

ENERGIZE

Compensatory changes in energy balance during dapagliflozin treatment in type 2 diabetes

ENERGIZE

Compensatory changes in energy balance during dapagliflozin treatment in type 2 diabetes
Funding Originally Bristol Myers Squibb (transitioned to Astra Zeneca)
Portfolio Clinical Specialties
Interventions Medicine
Randomised Yes
Status Closed
Start Date 31-Jul-2015

The University of Liverpool is conducting a clinical trial to help us identify how a new diabetes drug, dapagliflozin, helps people to lose weight. We would like to measure food intake and energy usage of selected patients before and after they have taken the drug for 3-months, and then after taking a placebo (dummy tablet) for the same period of time (a total of 6- months). Food intake is measured using a computerised eating monitor, and energy usage (called ‘metabolic rate’) using an instrument that measures gases breathed in and out. We will also look at how the drug affects the amount of fat in the body using a technique called magnetic resonance imaging (MRI), and how the brain responds to the images of food using a similar technique called functional magnetic resonance imaging (fMRI), which we are using to test for changes in appetite.

Publications

  • Rajeev SP, Sprung VS, Roberts C, Harrold JA, Halford JC, Stancak A, Boyland EJ, Kemp GJ, Cuthbertson DJ, Wilding JP. Compensatory changes in energy balance during dapagliflozin treatment in type 2 diabetes mellitus: a randomised double-blind, placebo-controlled, cross-over trial (ENERGIZE)-study protocol. BMJ Open. 2017 Jan 27;7(1):e013539. doi: 10.1136/bmjopen-2016-013539. PubMed PMID: 28132008; PubMed Central PMCID: PMC5278268.
    1. DOI: 10.1136/bmjopen-2016-013539